The effort to turn viruses into cancer-killing machines has suffered plenty of disappointments, but several companies are still investing in this branch of immuno-oncology. Here are some research programs to watch in the new year.

from Forbes – Tech http://ift.tt/2ibxDzu
via IFTTT